NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has reported progress in its Phase IIA clinical trial of NV-387 Oral Gummies for the treatment of Ebola Bundibugyo virus infection in the Democratic Republic of Congo. The exploratory trial, designed to enroll up to 20 patients with varying disease severity, is assessing the safety and tolerability of treatment regimens ranging from six to 12 days. While the study is not powered to establish statistically significant efficacy, it may identify preliminary signs of antiviral activity. This development matters because it represents a critical test of a novel broad-spectrum antiviral approach that, if successful, could be deployed rapidly against multiple viral threats, including Ebola, which lacks widely available, easy-to-administer treatments in outbreak settings.
Following completion of the trial and evaluation of results, NanoViricides plans to advance an appropriate dosing regimen into an expanded, randomized, controlled Phase IIB study, provided the findings support further development. NV-387 is a broad-spectrum antiviral candidate designed to reduce viral load by targeting host-cell features used by viruses during infection. Unlike many antivirals that target specific viral proteins, this host-directed mechanism could make it effective against a wide range of viruses and less prone to resistance. The oral gummy formulation is particularly significant for Ebola, as it could enable easier administration in resource-limited outbreak zones compared to injectable therapies. For investors, the progress de-risks the platform and opens the door to potential applications beyond Ebola, including RSV, COVID, influenza, and other infectious diseases.
NanoViricides is a clinical-stage company creating special-purpose nanomaterials for antiviral therapy. Its novel nanoviricide(TM) class of drug candidates is based on intellectual property, technology, and proprietary know-how of TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections, and even Measles. Another advanced candidate is NV-HHV-1 for the treatment of Shingles. The company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses. The company holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of human viral diseases including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses.
The trial’s outcome could have broad implications for global health security. Ebola outbreaks in the DRC and neighboring countries have been recurrent and deadly, with limited treatment options. An oral, broad-spectrum antiviral that can be stockpiled and deployed quickly would be a game-changer. Moreover, the host-cell targeting mechanism of NV-387 could potentially be effective against emerging viral threats, providing a first line of defense while strain-specific vaccines and therapies are developed. For NanoViricides, success in this trial would validate its platform and attract partnership or funding opportunities for larger trials. The company’s focus on advancing NV-387 into Phase II human clinical trials underscores its commitment to addressing unmet medical needs in infectious diseases.
To view the full press release, visit https://nnw.fm/9fDB5. For more information about NanoViricides, visit www.nanoviricides.com. The latest news and updates relating to NNVC are available in the company’s newsroom at https://nnw.fm/NNVC. NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. Please see full terms of use and disclaimers on the NetworkNewsWire website: https://www.NetworkNewsWire.com/Disclaimer.
